Brokerages Expect FibroGen Inc (NASDAQ:FGEN) to Post -$0.39 EPS

Equities research analysts expect that FibroGen Inc (NASDAQ:FGEN) will report earnings of ($0.39) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for FibroGen’s earnings, with the lowest EPS estimate coming in at ($0.82) and the highest estimate coming in at $0.03. FibroGen reported earnings of $0.23 per share during the same quarter last year, which would indicate a negative year over year growth rate of 269.6%. The business is expected to report its next quarterly earnings results on Wednesday, February 26th.

On average, analysts expect that FibroGen will report full year earnings of ($0.16) per share for the current fiscal year, with EPS estimates ranging from ($0.57) to $0.28. For the next year, analysts anticipate that the business will report earnings of ($0.56) per share, with EPS estimates ranging from ($1.76) to $1.43. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover FibroGen.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Monday, November 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.02. FibroGen had a net margin of 11.81% and a return on equity of 7.33%. The business had revenue of $33.17 million during the quarter, compared to analyst estimates of $31.61 million. During the same period last year, the business posted ($0.50) earnings per share. FibroGen’s quarterly revenue was up 14.3% compared to the same quarter last year.

FGEN has been the subject of several research analyst reports. TheStreet upgraded shares of FibroGen from a “d+” rating to a “c” rating in a report on Tuesday, August 13th. Zacks Investment Research lowered shares of FibroGen from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 14th. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a report on Thursday, October 17th. Mizuho restated a “buy” rating and issued a $72.00 price objective on shares of FibroGen in a report on Monday. Finally, ValuEngine upgraded shares of FibroGen from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. FibroGen currently has an average rating of “Buy” and a consensus price target of $58.33.

FGEN traded up $0.78 on Thursday, hitting $37.65. The company had a trading volume of 677,400 shares, compared to its average volume of 736,414. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.01 and a quick ratio of 8.95. FibroGen has a 52-week low of $32.33 and a 52-week high of $61.23. The stock has a fifty day simple moving average of $38.25 and a 200-day simple moving average of $41.47. The firm has a market capitalization of $3.23 billion, a P/E ratio of -36.55 and a beta of 1.84.

In other FibroGen news, CEO Thomas B. Neff sold 39,636 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $44.33, for a total transaction of $1,757,063.88. Following the completion of the transaction, the chief executive officer now owns 2,356,578 shares of the company’s stock, valued at $104,467,102.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Christine Chung sold 5,625 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $34.74, for a total transaction of $195,412.50. Following the transaction, the senior vice president now directly owns 145,253 shares of the company’s stock, valued at approximately $5,046,089.22. The disclosure for this sale can be found here. Insiders have sold 92,381 shares of company stock valued at $3,839,495 in the last ninety days. Insiders own 7.83% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Hillhouse Capital Advisors LTD. increased its stake in shares of FibroGen by 36.0% during the second quarter. Hillhouse Capital Advisors LTD. now owns 2,724,519 shares of the biopharmaceutical company’s stock valued at $123,094,000 after purchasing an additional 721,232 shares in the last quarter. Doheny Asset Management CA increased its stake in shares of FibroGen by 1.6% during the second quarter. Doheny Asset Management CA now owns 36,471 shares of the biopharmaceutical company’s stock valued at $1,648,000 after purchasing an additional 586 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of FibroGen by 13.2% during the second quarter. Janus Henderson Group PLC now owns 2,500,567 shares of the biopharmaceutical company’s stock valued at $112,976,000 after acquiring an additional 291,808 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of FibroGen by 6.9% during the second quarter. Envestnet Asset Management Inc. now owns 21,453 shares of the biopharmaceutical company’s stock valued at $969,000 after acquiring an additional 1,391 shares in the last quarter. Finally, HighTower Advisors LLC increased its position in shares of FibroGen by 67.5% during the second quarter. HighTower Advisors LLC now owns 43,040 shares of the biopharmaceutical company’s stock valued at $1,945,000 after acquiring an additional 17,351 shares in the last quarter. 69.71% of the stock is owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Story: Bond

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.